Sutro Biopharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value of Financial Assets and Liabilities Measured on Recurring Basis

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy:

	December 31, 2020
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	204,632	$	204,632	$	-	$	-
Commercial paper		42,208		-		42,208		-
Corporate debt securities		25,716		-		25,716		-
Equity securities		41,644		41,644		-		-
Asset-backed securities		12,632		-		12,632		-
U.S. government securities		39,785		39,785				-
Total	$	366,617	$	286,061	$	80,556	$	-

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	3,151	$	3,151	$	-	$	-
Commercial paper		4,952		-		4,952		-
Corporate debt securities		69,499		-		69,499		-
Asset-backed securities		27,055		-		27,055		-
U.S. government agency securities		27,007		-		27,007		-
Total	$	131,664	$	3,151	$	128,513	$	-